display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
locally advanced NSCLC - maintenance (M)
laNSCLC - M - all population
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone PACIFIC

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons